Intelligence / Healthtech / De Novo Grants / Biolinq Incorporated
Approvalsnovel device granted (FDA De Novo)23 Sept 2025
Biolinq Incorporated
23 Sept 2025: Novel device granted (FDA De Novo) · Biolinq Shine Autonomous Time-in-Range Microsensor. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 23 Sept 2025
- Device
- Biolinq Shine Autonomous Time-in-Range Microsensor
- Specialty
- Clinical Chemistry
- Product Code
- SFU
- Country
- United States
- Location
- San Diego, CA
- Submitted
- 2024-12-27
- Reference
- DEN240080
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Biolinq Incorporated
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Biolinq Incorporated in our registers.
More in Clinical Chemistry
De Novo Grants
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.